Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Apple wins $250 from Masimo in its smartwatch patent infringement case, but the victory doesn’t change much in its larger ...

Masimo (NASDAQ: MASI) today announced that Vanderbilt University Medical Center (VUMC), a renowned healthcare facility in ...

Apple has sought an injunction against health tech maker Masimo’s own smart watches, but it also netted the bare minimum for ...

The jury, in Delaware, agreed with Apple that previous iterations of Masimo’s W1 and Freedom watches and chargers willfully ...

A federal jury has found that Masimo smartwatches infringed on two of Apple's smartwatches, according to media reports.

This is the latest in a long battle between medical technology company Masimo and the tech giant, with Apple claiming that an ...